文献
J-GLOBAL ID:201702222132581939
整理番号:17A1708451
エルロチニブに進行する進行性非小細胞肺癌患者におけるソラフェニブと連続したエルロチニブまたはソラフェニブ単独:Sarah Cannon研究所(SCRI)の無作為化第II相試験【Powered by NICT】
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)
著者 (10件):
Spigel David R.
(Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN 37203, USA)
,
Rubin Mark S.
(Florida Cancer Specialists, Ft. Myers, FL 33905, USA)
,
Gian Victor G.
(Tennessee Oncology, PLLC, Nashville, TN 37203 USA)
,
Shipley Dianna L.
(Tennessee Oncology, PLLC, Nashville, TN 37203 USA)
,
Burris Howard A.
(Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN 37203, USA)
,
Kosloff Rebecca A.
(Florida Cancer Specialists, Ft. Myers, FL 33905, USA)
,
Shih Kent C.
(Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN 37203, USA)
,
Quinn Raven
(Sarah Cannon Research Institute, Nashville, TN 37203, USA)
,
Greco F. Anthony
(Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN 37203, USA)
,
Hainsworth John D.
(Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN 37203, USA)
資料名:
Lung Cancer
(Lung Cancer)
巻:
113
ページ:
79-84
発行年:
2017年
JST資料番号:
W3184A
ISSN:
0169-5002
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)